ArticleiLIVER2024
Setting up an integrated service for PSC-IBD patients: A quality improvement project.
Article in iLIVER, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
1 citing paper in PubMed.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
6 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Background and aims: Primary sclerosing cholangitis (PSC) often co-exists with inflammatory bowel disease (IBD) and together they are associated with increased risk of complications, including cancer (hepatobiliary, colorectal, gallbladder) and death. Guidelines for follow up and surveillance vary, but our local guidelines advise annual surveillance with magnetic resonance cholangiopancreatography (MRCP), colonoscopy and ultrasound (US) (6 monthly if cirrhotic). We aimed to assess the quality of care in our PSC-IBD patients, including adherence to local surveillance guidelines, and resultant detection of complications, before and after the introduction of an integrated PSC and IBD out-patient service. Methods: Data on management of PSC-IBD patients was collected retrospectively before, and prospectively following, the introduction of an integrated service. Descriptive comparisons of diagnoses, adherence to planned surveillance and outcomes were made between cohorts pre- and post-service redesign. Results: Prior to the service re-design there was significant variability in care and poor adherence to guidelines. Introduction of an integrated PSC-IBD service led to 89 referrals with possible PSC-IBD at 36 months after service re-design. Detailed review led to appropriate identification of 68 PSC-IBD patients. There was significant improvement in surveillance with annual colonoscopy in 90%, MRI/MRCP in 81%, US in 35%, compared to 55%, 55% and 7% respectively in the baseline cohort. This translated to diagnosis and appropriate treatment of colonic dysplasia in 4 patients, colorectal cancer (CRC) in 4 patients and cholangiocarcinoma (CCA) in 2 patients. Conclusion: Establishment of an integrated out-patient service for PSC-IBD patients results in better compliance with guidelines, effective detection of complications, and appropriate management.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.